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Objectives. The aim of the study was to screen 36 unrelated
patients with hypertrophic cardiomyopathy (HCM; 16 familial
and 20 sporadic cases) from a genetically homogeneous area in
eastern Finland for variants in the cardiac b-myosin heavy chain
(b-MHC) and a-tropomyosin (a-TM) genes.
Background. Mutations in the b-MHC and a-TM genes have
been reported to be responsible for 30% to 40% and less than 5%
of familial HCM cases, respectively. However, most genetic stud-
ies have included patients from tertiary care centers and are
subject to referral bias.
Methods. Exons 3-26 and 40 of the b-MHC gene and the nine
exons of the a-TM gene were screened with the PCR–SSCP
(polymerase chain reaction–single strand conformation polymor-
phism) method. Linkage analyses between familial HCM locus
and two intragenic polymorphic markers (MYO I and MYO II) of
the b-MHC gene were performed in 16 familial HCM kindreds.
Results. A previously reported Arg719Trp (arginine converted
to tryptophan in codon 719) mutation of the b-MHC gene was
found in one proband and two relatives. In addition, a novel
Asn696Ser (asparagine converted to serine in codon 696) substi-
tution was found in one HCM patient. No linkage between familial
HCM and the b-MHC gene was observed in 16 familial kindreds.
A previously reported Asp175Asn (aspartic acid converted to
asparagine in codon 175) mutation of the a-TM gene was found in
four probands and 16 relatives. Mutations in the b-MHC and
a-TM genes accounted for 6% and 25% familial HCM cases and
3% and 11% of all cases, respectively.
Conclusions. Our results indicate that the b-MHC gene is not
the predominant gene for HCM in the Finnish population,
whereas HCM caused by the Asp175Asn mutation of the a-TM
gene is more common than previously reported.
(J Am Coll Cardiol 1998;32:1709–16)
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Hypertrophic cardiomyopathy (HCM) is characterized by
myocardial hypertrophy accompanied with myocyte and myo-
fibrillar disarray (1,2). HCM occurs both as a sporadic form
and a familial disorder that is inherited as an autosomal
dominant trait (3). Hypertrophic cardiomyopathy is a geneti-
cally heterogeneous disease caused by defects in genes encod-
ing the following cardiac sarcomeric proteins: cardiac beta-
myosin heavy chain (b-MHC) (4–6), alpha-tropomyosin (a-
TM) (7–9), cardiac troponin T (7,8), cardiac myosin binding
protein C (10,11), and myosin essential or regulatory light
chain (12). Recently, mutations in the cardiac troponin I gene
have also been shown to be associated with familial HCM (13).
Missense mutations in the cardiac b-MHC gene have been
reported to be responsible for 30% to 40% of familial HCM
cases (6,14), whereas mutations in the cardiac troponin T gene
account for approximately 15% of cases (8). Mutations in the
a-TM and essential or regulatory chains of myosin genes are
uncommon causes of HCM, accounting for ;5% and ,1% of
cases, respectively (8,15,16).
Most of our knowledge of HCM including genetic analyses
is derived from studies performed at tertiary care centers, and
is profoundly influenced by referral bias (17). Thus, the gene
defects accounting for HCM may be distributed differently in
the general population. However, so far no genetic studies in
unselected populations have been published.
The Finnish population is genetically quite homogeneous,
descending mainly from a small number of founders of Baltic
and German origin (18). Therefore, the Finnish population
offers a unique possibility to investigate the genetic basis of any
disease. We used polymerase chain reaction (PCR)–single
strand conformation polymorphism (SSCP) analysis to inves-
tigate variants in exons 3-26 and 40 of the cardiac b-MHC gene
and in each of the nine exons of the a-TM gene in an
unselected population of 36 unrelated Finnish HCM patients.
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Methods
Index patients. The Kuopio University Hospital region in
eastern Finland covers a population of 250,000. All patients
with suspected or confirmed HCM in this area are sent to the
Division of Cardiology of the Department of Medicine of the
Kuopio University Hospital for diagnosis and treatment. In
this study, all unrelated patients who had suspected or con-
firmed HCM according to hospital discharge records and
previous medical records were evaluated at the Kuopio Uni-
versity Hospital by the same cardiologist (J.K.). Altogether, 36
unrelated patients aged over 16 years and fulfilling the criteria
for HCM were included in the study group.
Clinical evaluation. All subjects underwent an interview,
physical examination, 12-lead electrocardiogram, M-mode and
two-dimensional echocardiography, Doppler echocardiogra-
phy, and a 24-h Holter electrocardiographic (ECG) registra-
tion. Physical examination included measurement of height,
weight and blood pressure. Blood pressure was measured twice
on the right arm with a standard sphygmomanometer after
10 min of bed rest with a 2-min interval. The latter value was
used in statistical analyses. A venous blood sample for genetic
analyses was obtained after securing informed consent. Affec-
tion status was ascertained without knowledge of the results of
genetic analysis.
Echocardiographic evaluation was performed with a
Hewlett-Packard Sonos 1000 scanner with a 2.5-MHz trans-
ducer. The M-mode tracings (paper speed 100 mm/s) were
obtained with simultaneous electrocardiograms (ECG). All
tracings were analyzed with custom-built software by two
observers (J.K. and K.S.) without knowledge of the clinical
status of the subjects. By using a digitizing table (MM 1201,
Summagraphics Co., Fairfield, Connecticut; resolution
0.1 mm), the M-mode measurements were obtained from three
cycles and averaged. All measurements were performed ac-
cording to the standards of the American Society of Echocar-
diography (19).
The diagnosis of hypertrophic cardiomyopathy (HCM) was
based on demonstration of maximal left ventricular (LV) wall
thickness of at least 15 mm on two-dimensional echocardiog-
raphy in the absence of other causes for ventricular hypertro-
phy, such as hypertension. Subjects were defined as having
hypertension if systolic blood pressure was .160 mm Hg or
diastolic blood pressure .100 mm Hg, or if the subject was
receiving drug treatment for hypertension. Affection status for
HCM in adult relatives of the probands was based on the
diagnostic criteria by McKenna et al. (20). Briefly, relatives
with LV wall thickness of at least 13 mm in the absence of
other causes for ventricular hypertrophy were classified as
having HCM. Relatives with LV wall thickness $13 mm but
also with definite or borderline hypertension or a body mass
index (BMI) $35 kg/m2, were classified as having suspect
HCM. Relatives ,16 years of age were diagnosed to have
HCM by pediatric cardiologist (T.T.) if the thickness of the
interventricular septum on echocardiography exceeded the
average values of subjects with similar body surface area by at
least 2 SD (21) and if they had ECG signs of LV hypertrophy
and/or symptoms supporting the diagnosis. The study protocol
was approved by the Ethics Committee of the University of
Kuopio and was in accordance with the Helsinki Declaration.
Single strand conformation polymorphism analysis (PCR–
SSCP). The DNA was prepared from peripheral blood leuko-
cytes by the proteinase K-phenol-chloroform extraction
method. Intronic sets of primers flanking each of the exons
from 3 to 26 and 40 of the cardiac b-MHC gene were designed
according to the reported sequences of the cardiac b-MHC
gene (22,23). Primers for the exons 1a, 2b, 3, 4, 5, 6b, 7, 8 and
9a,b of the striated muscle isoform of the a-TM gene were
synthesized as previously reported (7). Each of the exons of the
cardiac b-MHC gene and of the a-TM gene were amplified
with the polymerase chain reaction (PCR). The reaction
mixture of 10 ml consisted of 50 ng genomic DNA, 5 pmol of
each primer, 10 mmol/liter Tris-HCl (pH 8.8), 50 mmol/liter
KCl, 1.5 mmol/liter of MgCl2, 0.1% Triton X-100, 200 mmol/
liter dNTP, 0.25 U of DNA polymerase (Dynazyme DNA
polymerase, Finnzymes, Finland) and 1.0 mCi of alpha 32P
dCTP. The PCR conditions for the b-MHC gene were dena-
turation at 94°C for 3 min, followed by 35 cycles of denatur-
ation at 94°C for 40 s, annealing at 56–66°C for 30 to 60 s and
extension at 72°C for 30 to 60 s with final extension at 72°C for
4 min. The PCR conditions for the a-TM gene were as
previously described (7) with an addition of the 3-min dena-
turation in 94°C and the final extension of 4 min at 72°C. The
SSCP analysis was performed essentially according to the
method of Orita et al. (24).
To obtain fragments ,270 base pairs (bp) long, PCR
products were digested with an appropriate restriction enzyme
if necessary. For SSCP analysis, PCR products were first
diluted 2–20-fold with 0.1% sodium dodecyl sulfate (SDS), 10
mmol/liter EDTA and then diluted (1:1) with loading mix
(95% formamide, 20 mmol/liter EDTA, 0.05% bromphenol
blue, 0.05% xylene cyanol). After denaturation at 98°C for
3 min, samples were immediately cooled on ice, and 2 ml of
each sample was loaded onto 5% (PCR products .200 bp) or
6% (PCR products #200 bp) nondenaturing polyacrylamide
gel (acrylamide/N,N-methylene-bis-acrylamide ratio 49:1)
containing 10% glycerol. Each sample was run at two different
gel temperatures: 1) at 38°C for approximately 4 h and 2) at
29°C for approximately 5 h. The gel was autoradiographed
overnight at 270°C with intensifying screens.
Abbreviations and Acronyms
a-TM 5 alpha-tropomyosin
Arg719Trp 5 arginine converted to tryptophan in codon 719
Asn696Ser 5 asparagine converted to serine in codon 696
Asp175Asn 5 aspartic acid converted to asparagine in codon 175
b-MHC 5 beta-myosin heavy chain
HCM 5 hypertrophic cardiomyopathy
PCR 5 polymerase chain reaction
SSCP 5 single strand conformation polymorphism
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Direct sequencing. Genomic DNA from individuals with
variant single strand conformers was used as a template in the
amplification reaction as described above (total volume 50 ml
containing 25 pmol of each primer and 1.25 U of Dynazyme
DNA polymerase). Amplified PCR products were purified by
electrophoresis on a 1% low-melting-point agarose gel and
directly sequenced using Sequenase version 2.0 DNA polymer-
ase (US Biochemicals, Cleveland, Ohio) as previously de-
scribed (25).
Restriction fragment length polymorphism (RFLP) analy-
sis. A novel amino acid substitution (Asn696Ser) (asparagine
converted to serine in codon 696) found in the cardiac b-MHC
gene was verified by digestion of the variant PCR product with
the restriction endonuclease BsrD1. The AAT696AGT substi-
tution abolishes a BsrD1 restriction site. Therefore, the sub-
stitution was confirmed by digestion of the variant PCR
fragment by BsrD1 restriction enzyme. Digestion of the 198-bp
heterozygous PCR product with BsrD1 yields a 198-bp frag-
ment in case of Asn696Ser substitution in addition to the
normal 90-bp and 108-bp products. Digested fragments were
then electrophoresed on a 3% agarose gel (NuSieve GTG,
FMC Bioproducts, Rockland, Maine).
Detection of polymorphic markers. Primers for intragenic
dinucleotide microsatellite markers MYO I and MYO II of the
b-MHC gene (26) and HTMaCA of the a-TM gene (7) were
synthesized. The primers used for the amplification of the
MYO I and MYO II were as follows: MYO I: primer F, 59
ATCTGAGCATATGGGACCAAT 39; primer R, 59 TCATA-
CACCCACATCTCCCA 39; MYO II: primer F, 59 CAG-
CAACTGGATGATGTGAGTAG 39; primer R, 59 ATCAC-
CACCTCTGACTTTTCATT 39. Primers for the HTMaCA
were as previously reported (7). One of the primers for
amplification of the microsatellite markers was labeled with
fluorescein during synthesis. The polymorphic DNA fragments
were amplified with PCR at optimized conditions. The elec-
trophoresis separating dinucleotide alleles of different sizes
was carried out with an automated laser fluorescence DNA
sequencer (ALFexpress, Pharmacia, Uppsala, Sweden) with
6% Hydrolink gels. Two internal size standards were included
in each lane.
Statistical analysis. All calculations were performed with
the SPSS/WIN programs (SPSS, Chicago, Illinois). Data are
presented as mean 6 SEM. The characteristics of the pro-
bands with sporadic and familial HCM were compared with
the x2 test and Student’s two-tailed t test for independent
samples, when appropriate. Two-point pairwise linkage analy-
sis was performed using the MLINK program of the LINK-
AGE 5.2 package (27,28). Dominant inheritance mode was
used for HCM with a penetrance of 0.95. Allele frequencies for
the MYO I and MYO II markers in population were estimated
from the sample of 70 randomly selected healthy men from
eastern Finland. Subjects with an uncertain diagnosis were
assigned an unknown status in the linkage analysis. Heteroge-
neity between the families was tested using the HOMOG
program (28). Conventional criteria for the evidence of linkage
(LOD [logarithm of the odds] score .3) and the exclusion of
linkage (LOD score ,22) between the markers and HCM
were applied.
Results
Clinical findings. All but one of the 36 probands fulfilled
the aforementioned diagnostic criteria for HCM. This proband
(family no. 8), otherwise fulfilling the criteria for HCM, had
hypertension but was included in the study because she had
one first-degree relative and one second-degree relative with a
definite HCM. Fourteen of the 36 probands had a definite
family history of HCM (both the proband and at least one
first-degree relative fulfilling the diagnostic criteria for definite
HCM). In addition, two more probands had at least one
first-degree relative with suspected HCM. The remaining 20
probands had no known family history of HCM.
Clinical characteristics of the probands are shown in Table
1. The study group included 21 men and 15 women with a
mean age of 49.3 years. Sex distribution was different between
the probands, with sporadic (15 men, 5 women) and familial
HCM (6 men, 10 women; p 5 0.023). Most of the subjects had
been diagnosed as having HCM before our study (86%). Three
subjects had a history of cardiac failure, and three subjects had
undergone a myotomy-myectomy operation. The most com-
mon cardiac symptoms were dyspnea and syncope/presyncope.
Only 11% of the subjects had a history of constant atrial
fibrillation. The probands with sporadic HCM had higher
Table 1. Clinical Characteristics of the Probands With HCM
Characteristics n 5 36
Men/Women 21/15
Age (yr) 49.3 6 2.7
History of cardiac failure 3 (8%)
History of myectomy 3 (8%)
Cardiac symptoms 32 (89%)
Dyspnea 27 (75%)
Chest pain 7 (19%)
Presyncope/syncope 15 (42%)
No symptoms 4 (11%)
Constant atrial fibrillation 4 (11%)
Systolic BP (mm Hg) 131 6 2
Diastolic BP (mm Hg) 80 6 2
Abnormal auscultation 35 (97%)
S4 without systolic murmur 7 (19%)
Systolic murmur without S4 4 (11%)
S4 1 systolic murmur 24 (67%)
Abnormal ECG 36 (100%)
LAH 11 (31%)
LVH 27 (75%)
Pathological Q-waves 17 (47%)
Abnormal T-waves 29 (81%)
Abnormal ST-level 18 (50%)
BP, blood pressure; ECG, electrocardiogram; HCM, hypertrophic cardio-
myopathy; LAH, left atrial hypertrophy; LVH, left ventricular hypertrophy.
Value for abnormal T-waves includes giant and negative T-waves. Value for
abnormal ST-level includes $1 mm depression or elevation of ST-level. Data are
mean 6 SEM or n (%).
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systolic blood pressure than did the probands with familial
HCM (135 6 3 vs. 125 6 2 mm Hg; p 5 0.017). Nearly all
subjects had both abnormal auscultation and ECG findings.
Most subjects (75%) had left ventricular hypertrophy on ECG,
and almost half of the subjects had pathological Q-waves on
ECG. Eight subjects were diagnosed with short bursts of
ventricular tachyarrhythmias on Holter examination.
Echocardiographic data are shown in Table 2. The mean
maximal thickness of the interventricular septum (IVS) on
two-dimensional echocardiography was 24.1 mm (range 15.4 to
36.1 mm). The maximal hypertrophy was located in the IVS in
nearly all of the subjects. Left ventricular end systolic and end
diastolic dimensions were within normal limits. Left ventricular
end diastolic dimension was greater in the probands with
sporadic HCM than in the probands with familial HCM
(47.7 6 1.5 vs. 41.5 6 2.6 mm; p 5 0.039). Systolic anterior
motion of the mitral valve was present in four patients (11%),
and only three (8%) had a LV outflow tract obstruction.
Detection of sequence variants in the b-MHC gene. Exons
from 3 to 26 and 40 of the b-MHC gene were screened with the
PCR–SSCP method. Sequencing of abnormally migrating
DNA fragments revealed a total of eight different variants. A
missense mutation previously reported to cause HCM was
found in exon 19 (Arg719Trp) (arginine converted to trypto-
phan in codon 719) in the proband of family no. 25 (Table 3
and Fig. 1a). All available relatives of the proband were both
clinically and genetically studied. The mutation was found in
two of the proband’s young children (individuals IV-2 and
IV-3) but in none of the clinically unaffected relatives.
In addition, a novel AAT to AGT substitution in exon 19 of
the b-MHC gene resulting in a substitution of asparagine to
serine at residue 696 was identified in one HCM patient
(heterozygous). This patient was a 12-year-old not belonging to
the original study group of 36 probands. He had been clinically
evaluated at the Department of Pediatrics of the Kuopio
University Hospital and had a definite HCM with septal and
apical hypertrophy.
Other sequence variants (numbered according to reference
22) we found in the cardiac b-MHC gene included four silent
nucleotide substitutions (ACC63ACT, TTT244TTC,
ACG786ACA and ATT989ATC), an intronic nucleotide sub-
stitution (nucleotide 8935 T3C) and a nucleotide substitution
at the 39 noncoding region of exon 40 (position 6007 G3A).
None of these six variants co-segregated with the disease in
families.
Identification of the Asp175Asn substitution in the a-TM
gene. A previously reported missense mutation (Asp175Asn)
(aspartic acid converted to asparagine in codon 175) in exon 5
of the a-TM gene was found in four probands (families no. 1,
11, 39 and 45; Table 3 and Fig. 1b). Most first-degree relatives
and some of the second-degree relatives of these four pro-
bands were both clinically and genetically studied. Altogether
20 probands and relatives from the four families carried the
mutation. No other sequence variants were found in the a-TM
gene.
Linkage analysis. Linkage analysis was performed in 16
families with confirmed or suspected familial HCM using the
intragenic polymorphic markers MYO I and MYO II of the
cardiac b-MHC gene (Table 4). No evidence of linkage was
found between the HCM locus and markers MYO I (Z 5
211.43, u 5 0) and MYO II (Z 5 218.78, u 5 0). Allowing
heterogeneity between families did not change the results. In
six families (1, 8, 12, 17, 39 and 45) individual LOD (logarithm
of the odds) scores for either MYO I or MYO II indicated the
exclusion of linkage between HCM and the b-MHC gene. The
LOD scores for the rest of the families provided little or no
evidence supporting or refuting linkage to the b-MHC locus.
To investigate the possible founder effect of the Asp175Asn
substitution of the a-TM gene in families 1, 11, 39 and 45,
DNA samples from the members of these families were
genotyped for the intragenic microsatellite marker HTMaCA.
All family members with the Asp175Asn substitution carried
the same allele (no. 5) of the marker (Fig. 1b).
Table 3. Mutations in the Cardiac Beta-Myosin Heavy Chain
(b-MHC) and Alpha-Tropomyosin (a-TM) Genes Causing
Hypertrophic Cardiomyopathy
b-MHC
Arg719Trp
b-MHC
Asn696Ser
a-TM
Asp175Asn
Nucleotide change CGG3TGG AAT3AGT GAC3AAC
No. of probands (n 5 36)
with mutation
1 0* 4
No. of relatives with
mutation
2 not screened 16
Percentage of probands
with familial HCM
with mutation
6% 0%* 25%
*The patient with HCM carrying the Asn696Ser substitution did not belong
to the original study group of 36 probands.
Table 2. Echocardiographic Findings in the Probands With HCM
Echocardiographic Findings n 5 36
2D IVS (mm) 24.1 6 0.8
Location of maximal hypertrophy
Septum 34 (94%)
Free wall 1 (3%)
Concentric 1 (3%)
Left ventricular posterior wall (M-mode, mm) 11.0 6 0.4
LVEDD (mm) 44.9 6 1.5
LVESD (mm) 28.9 6 1.3
FS (%) 36.7 6 1.5
Base of aorta (mm) 33.2 6 1.0
Left atrium (mm) 40.5 6 1.5
Mitral regurgitation 12 (33%)
SAM 4 (11%)
Obstruction at LV outflow tract 3 (8%)
VMAX (m/s) 1.21 6 0.06
2D IVS, maximal thickness of interventricular septum on two-dimensional
echocardiography; FS, fractional shortening; LV, left ventricle; LVEDD, left
ventricular end diastolic dimension; LVESD, left ventricular end systolic dimen-
sion; SAM, systolic anterior motion of mitral valve; VMAX, maximal flow
velocity in the left ventricular outflow tract. Data are mean 6 SEM or n (%).
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Discussion
Study population. Finland is known for its “Finnish disease
heritage,” meaning that uncommon genetic, mostly recessive,
Figure 1a. Pedigrees of the families carrying (a) cardiac b-myosin
heavy chain gene Arg719Trp and (b) a-tropomyosin gene Asp175Asn
substitutions. Alleles for intragenic microsatellite markers (a) MYO I
and MYO II and (b) HTMaCA are depicted under each family member.
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disorders are enriched or only encountered in Finland (18,29).
Because of genetic isolation, the Finnish population, particu-
larly in eastern Finland, is an ideal population to investigate
distribution of different variants responsible for HCM. In the
present study all known and suspected HCM patients of the
Kuopio University Hospital region, encompassing a population
of about 250,000, were included. Therefore, our study popula-
tion is probably representative of all symptomatic HCM cases
in the study area and very likely reflects the distribution of gene
defects causing HCM in the Finnish population, at least in the
eastern part of the country.
Screening of variants in the b-MHC and a-TM genes. We
screened the exons encoding the head and hinge regions (and
exon 40 encoding the 39-end of the rod region) of the cardiac
b-MHC gene and the nine exons of the a-TM gene in 36
unselected Finnish patients with HCM. Only two amino acid
substitutions (Arg719Trp and Asn696Ser) in exon 19 of the
b-MHC gene were found. A previously reported mutation
(Asp175Asn) in exon 5 of the a-TM gene was found in four
probands. These data indicate that, unlike in other European
HCM kindreds (6), the cardiac b-MHC gene is not the
predominant gene for HCM in the Finnish population because
it accounted for only ;3% of all cases and less than 10% of
familial cases. In contrast, the Asp175Asn substitution of the
a-TM gene was a substantially more common cause for HCM
than previously reported (8). This substitution was found in
11% of all cases and in approximately 25% of familial cases.
Accordingly, a recent study of Japanese HCM patients
indicated that mutations in the b-MHC gene are not the
predominant cause for HCM in Japanese patients (30). These
results imply genetic heterogeneity of HCM among different
populations.
Interestingly, in our study all patients with the Asp175Asn
substitution from four unrelated kindreds carried the same
repeat sequence allele of the HTMaCA marker. Hence, the
Asp175Asn mutation may have arisen from a common ances-
tor in these families. Recently, Coviello et al. (31) described
three European HCM kindreds with the Asp175Asn substitu-
tion arising from independent origins, suggesting that the
codon 579 of the a-TM gene is a mutational hot spot.
Patients with the variants in the b-MHC gene. The pro-
band of family 25 (Fig. 1a) with the Arg719Trp substitution of
the b-MHC gene was 28 years old and had been diagnosed
with HCM at the age of 18. The maximal thickness of the
interventricular septum (IVS) was 25.0 mm. The oldest of the
proband’s children (individual IV-1, age 4 years) was normal
by echocardiography and did not carry the mutation. The older
of the proband’s two children carrying the mutation (individual
IV-2, age 2 years) had definite HCM (IVS thickness of 8 mm
[12 SD]). The proband’s youngest child (individual IV-3, age
1 year) had the mutation but did not fulfill the echocardio-
graphic criteria for HCM (IVS thickness of 5.5 mm [10.5 SD]).
The proband’s mother (individual II-2) did not carry the
Arg719Trp substitution although her IVS was 17.0 mm thick
and there were no other obvious causes for the hypertrophy.
The proband’s father (individual II-1) died of cancer at the age
of 45 and did not have medical history indicating HCM. The
proband’s brother (individual III-2) also showed left ventricu-
lar (LV) hypertrophy with IVS thickness of 14.2 mm but did
not carry the Arg719Trp substitution. He had been a profes-
sional athlete and was still exercising intensively, which was the
probable cause for mild LV hypertrophy.
The origin of the Arg719Trp substitution of the cardiac
b-MHC gene in family 25 is uncertain. The proband’s mother
did not carry the mutation, although she fulfilled the echocar-
diographic criteria for HCM. Therefore, it is possible that the
mutation has arisen de novo in the proband, who has trans-
mitted it to two of her three children. On the basis of haplotype
analysis of the markers MYO I and MYO II, this seems
possible because the proband and her genetically unaffected
brother (individual III-2 of the family 25) share the same
alleles of both markers (Fig. 1a). Alternatively, the proband
has inherited the mutation from her father, but her brother
(individual III-2) has inherited a recombination of alleles
MYO I and MYO II.
The patient with the Asn696Ser substitution of the b-MHC
gene was 9 years old when diagnosed with HCM. Echocardi-
ography showed asymmetrical hypertrophy of the apical and
IVS with a maximal IVS thickness of 17.0 mm. He had no
symptoms until he died suddenly during exertion. The pres-
ence of the Asn696Ser substitution among relatives could not
be studied because the patient had been adopted and samples
were not available from the biological parents or other rela-
tives. The Asn696Ser substitution does not change the charge
of the cardiac b-MHC protein. However, because the mutation
was located in the region critical for adenosine triphosphate
Table 4. LOD Scores of the Two-Point Linkage Analysis Between
Familial HCM Locus (Dominant Inheritance Mode With a
Penetrance of 95%) and Two Polymorphic Markers MYO I and
MYO II of the Cardiac b-Myosin Heavy Chain Gene With
Recombination Fractions (u) 0 and 0.01 in 16 Families With
Confirmed or Suspected Familial HCM
Family n
MYO I MYO II
u 5 0 u 5 0.01 u 5 0 u 5 0.01
All 133 211.43 29.45 218.78 212.24
1 16 22.33 22.25 22.22 21.03
7 4 20.16 20.15 20.22 20.21
8 15 21.96 21.71 23.10 22.21
11 4 0.00 0.00 0.00 0.00
12 11 0.32 0.32 22.20 21.34
15 10 0.10 0.15 0.72 0.71
17 4 0.00 0.00 23.24 21.40
18 6 21.02 20.88 20.90 20.80
19 8 20.20 20.20 20.22 20.22
25 9 21.22 21.06 21.37 21.19
26 10 20.65 20.54 20.68 20.58
28 6 20.76 20.68 0.07 0.07
37 5 20.46 20.43 20.46 20.39
39 9 20.39 20.35 22.38 21.11
40 7 20.32 20.31 20.49 20.47
45 9 22.38 21.36 22.09 22.07
LOD, logarithm of the odds.
1714 JA¨A¨SKELA¨INEN ET AL. JACC Vol. 32, No. 6
GENE DEFECTS IN HYPERTROPHIC CARDIOMYOPATHY November 15, 1998:1709–16
(ATP) and actin binding sites, which is highly conserved among
different species (22), the Asn696Ser substitution was likely to
be the cause for HCM in this patient.
Patients with the Asp175Asn mutation. In patients with the
Asp175Asn substitution of the a-TM gene (4 probands and 16
relatives), mean maximal thickness of the IVS was 18.9 mm
(range 11.2 to 30.0 mm). Three individuals (family no. 1,
individual II-1; family no. 11, individual II-1; family no. 45,
individual III-2; Fig. 1b) carrying the Asp175Asn substitution
had hypertension; therefore, they were clinically classified to
have suspect HCM. Individual II-5 of family no. 1 and individ-
uals I-2 and II-5 of family no. 39 (Fig. 1b) were classified to
have suspect HCM because they had left ventricular hypertro-
phy and also high blood pressure values. None of them carried
the mutation. In family no. 39, the Asp175Asn mutation was
inherited from the proband’s father (individual I-1), who had
died suddenly at the age of 48, and cardiomyopathy (most
likely HCM) was diagnosed at autopsy.
Screening of variants. The SSCP generally detects ;80%
of all mutations. To increase the probability of finding se-
quence variants, we screened all exons at two different tem-
peratures. Furthermore, all the PCR fragments were ,270 bp
in length to maximize the probability of finding mutations in
the b-MHC and a-TM genes. The method we used has been
shown to detect all sequence variants of the lipoprotein lipase
gene (32,33), and it has also been successfully applied in the
screening of the green and red opsin genes (34,35) and the
insulin receptor substrate-1 gene (36). Therefore, it is not
likely that we have missed a significant number of sequence
variants in the b-MHC and a-TM genes.
Conclusions. We conclude that the cardiac b-myosin heavy
chain gene is not the predominant disease-causing gene for
HCM in the Finnish population because it accounted for less
than 10% of familial and 3% of all cases of HCM. In contrast,
the Asp175Asn mutation in the a-tropomyosin gene was more
common than previously reported (8), accounting for approx-
imately 25% of Finnish familial HCM cases. Therefore, this
substitution could be the predominant gene defect leading to
familial HCM in the Finnish population. Because the Finnish
population has descended from a small number of founders it
is possible that many probands in our patient population may
have a common ancestor. Thus, only a few mutations might
account for the majority of HCM cases. Interestingly, none of
the sporadic HCM cases were caused by mutations in the
b-MHC gene or a-TM gene, and over half of the familial HCM
cases were not caused by defects in the aforementioned genes
either. Consequently, the major genes responsible for HCM in
the Finnish population are yet to be identified.
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